Deferred radiotherapy and upfront procarbazine–ACNU–vincristine administration for 1p19q codeleted oligodendroglial tumors are associated with favorable outcome without compromising patient performance, regardless of WHO grade
Open Access
- 1 November 2016
- journal article
- research article
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 9, 7123-7131
Abstract
Recently updated phase III trials revealed the favorable effect of add-on procarbazine-lomustine-vincristine chemotherapy (CT) to radiotherapy (RT) in treating anaplastic oligodendrogliomas with 1p19q codeletion (codel). However, the underlying rationality of deferring RT and upfront CT administration for these tumors is yet to be elucidated. Here, we retrospectively analyzed the long-term outcome of our case series with oligodendroglial tumors treated with deferred RT and upfront procarbazine+nimustine+vincristine (PAV) in the introduction administration. We enrolled 36 patients with newly diagnosed oligodendroglial tumors (17, grade II and 19, grade III) treated during 1999–2012 and followed up for a median period of 69.0 months. Their clinical and genetic prognostic factors were analyzed, and progression-free survival, overall survival (OS), and deterioration-free survival (DFS) were evaluated. Regardless of the WHO grade, the 25 patients with 1p19q codel tumors never received RT initially, and of these 25, 23 received PAV treatment upfront. The 75% OS of patients with 1p19q codel tumor was 135.3 months (did not reach the median OS), indicating a favorable outcome. Multivariate analysis revealed that IDH mutation and 1p19q, not WHO grade, are independent prognostic factors; furthermore, IDH and 1p19q status stratified the cohort into 3 groups with significantly different OS. The DFS explained the prolonged survival without declining performance in patients with both grade II and III 1p19q codel tumors. Deferred RT and upfront PAV treatment for 1p19q codel oligodendrogliomas were associated with favorable outcomes without compromising performance status, regardless of WHO grade.Keywords
This publication has 29 references indexed in Scilit:
- Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951Journal of Clinical Oncology, 2013
- Initial treatment patterns over time for anaplastic oligodendroglial tumorsNeuro-Oncology, 2012
- International retrospective study of over 1000 adults with anaplastic oligodendroglial tumorsNeuro-Oncology, 2011
- All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2Neurology, 2010
- Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomasNeuro-Oncology, 2010
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working GroupJournal of Clinical Oncology, 2010
- Survey of treatment recommendations for anaplastic oligodendrogliomaNeuro-Oncology, 2007
- A t(1;19)(q10;p10) Mediates the Combined Deletions of 1p and 19q and Predicts a Better Prognosis of Patients with OligodendrogliomaCancer Research, 2006
- Two types of chromosome 1p losses with opposite significance in gliomasAnnals of Neurology, 2005
- Successful chemotherapy for recurrent malignant oligodendrogliomaAnnals of Neurology, 1988